Tag: psilocybin

Military To Start Testing Service Members For The Psychedelic Psilocin, Memo Shows

The U.S. Department of Defense (DOD) is expanding the list of drugs that military service members will be tested for to include the psychedelic compound psilocin, one of the two main components of psilocybin mushrooms.

In a memo obtained by Marijuana Moment, a DOD employee performing the duties of the deputy under secretary of defense for personnel and readiness advised military leadership that psilocin will be added to the department’s Drug Demand Reduction Program drug testing panel effective October 1.

The memo, dated August 18, states that the policy change being made due to “the risk of impairment and subsequent deterioration of security, military fitness, readiness, good order and discipline.”

“Drug abuse by Service members is a safety and readiness issue, and the Department must adapt our detection and deterrence program to address new and emerging drug threats,” Dr. Merlynn Carson wrote.

The DOD official said that attachments to the memo lay out “cutoff concentrations” for a positive psilocin test and other drugs in the testing panel.

Marijuana Moment reached out to DOD for copies of those attachments, but representatives were not able to immediately provide the documents.

“The Department of Defense maintains a zero-tolerance policy prohibiting drug use, and we remain committed to continually expanding drug testing capabilities and enhancing our education and prevention efforts by providing effective information on drug misuse, including the use of Psilocin,” an official told Marijuana Moment in an email.

The memo says that the “first priority” for psilocin testing under the revised drug panel “will be given to specimens collected under the auspices of probable cause, consent, or command.”

“In proportion to laboratory capabilities and capacity, second priority will be given to special testing requests for other collection modes, such as routine inspection-based collections, and specimens may also be randomly tested for psilocin,” it says.

At the same time that DOD has moved to test for psilocin, it’s also carrying out a congressional mandated psychedelic therapy pilot program for active duty service members and veterans. A more recent spending bill covering DOD would require a “progress report” on that initiative.

This latest memo also comes about two months after a DOD contractor sued the federal government, alleging that questions about his past marijuana use during a security clearance process violated his Fifth Amendment right against self-incrimination.

While the latest DOD policy update concerned a psychedelic compound, questions about federal workers testing positive for marijuana have also ballooned in recent years, as more individual states have legalized the drug.

Keep reading

Single dose of psilocybin provides lasting relief from depression and anxiety in cancer patients

A clinical trial examined the effects of psilocybin combined with psychological support on cancer patients diagnosed with major depressive disorder. Results showed that a single dose of psilocybin had robust antidepressant effects in these individuals. Fifty percent demonstrated sustained depression reduction, while 43% experienced a sustained reduction in anxiety. The research was published in the journal Cancer.

Depression is a mental health condition that involves persistent sadness, loss of interest, and feelings of hopelessness. It is often accompanied by anxiety, which is characterized by excessive fear, worry, and physical tension. Both conditions are common psychological responses to the challenges of living with cancer.

Cancer patients often face uncertainty about their prognosis, undergo painful treatments, and experience changes in physical functioning, all of which can heighten anxiety. Depression may develop as a response to the emotional burden of diagnosis, fatigue, changes in body image, or loss of independence. These conditions can negatively affect treatment adherence, as patients may avoid appointments or struggle to follow medical recommendations.

Anxiety can also intensify physical symptoms such as pain, nausea, or insomnia, creating a cycle of distress. Depression may reduce motivation and energy, limiting the patient’s ability to engage in daily activities and draw on social support. Emotional distress in cancer patients is associated with a poorer quality of life and, in some studies, worse clinical outcomes.

Study author Manish Agrawal and his colleagues explored the impact of psilocybin combined with psychological support in 30 patients with cancer and a diagnosis of major depressive disorder. Some had curable, and others had incurable forms of cancer. The average age of participants was 57.5 years, and 19 were female. None were hospitalized for depression at baseline, and 61% were not receiving psychiatric medications. During the course of the study, two patients died, reducing the number of participants in the final analysis to 28.

Keep reading

Psilocybin Can ‘Maximize’ Recovery From Traumatic Brain Injury, Scientific Review Concludes

Psilocybin, a main chemical component in psychedelic mushrooms, could play a beneficial role in patients recovering from traumatic brain injury (TBI), according to a new scientific review published in the journal Brain Science.

Reviewing 29 published studies about the use of psilocybin in patients with TBI, a three-person team from Hackensack Meridian School of Medicine and Hackensack Meridian’s JFK Johnson Rehabilitation Institute concluded that assisted psilocybin use “may have benefits in TBI by reducing inflammation, promoting neuroplasticity and neuroregeneration, and alleviating associated mood disorders.”

That conclusion, along with “positive findings in related fields, like treatment for depression and addiction, highlight the necessity for more extensive clinical trials on psilocybin’s role in TBI recovery,” authors wrote.

“The research on psilocybin as a therapeutic agent shows promise for its application in TBI in theory,” the new review says, “but it requires more in-depth studies.”

The report points to psilocybin’s apparent anti-inflammatory properties and its ability to promote the production of new neurons and connections in the brain. It also says the drug’s antidepressant properties could be helpful given the comparatively high rates of depression in TBI patients.

But the new paper also flags “concerns regarding potential ‘bad trips’ and other possible side effects,” emphasizing the “need for more controlled clinical trials to establish safe and effective protocols.”

Notably, the review found no indication that classical psychedelics were associated with an increase risk of seizures, which authors said was important given the heightened incidence of seizures already associated with TBI.

Authors emphasized that federal restrictions on psilocybin limit researchers’ abilities to easily conduct trials, writing that although “decriminalization efforts in the United States are indicative of growing interest, its federal Schedule I classification limits rigorous scientific exploration.”

Overall, the paper says, “psilocybin treatment with current therapeutic practices has the potential to maximize TBI recovery, thus providing a novel method to enhance treatment for people dealing with this persistent condition.”

The research comes amid a renewed interest in psychedelics to treat mental health and medical conditions, including TBI and post-traumatic stress disorder (PSTD), especially in military veterans.

Keep reading

Germany Establishes EU’s First Psilocybin Compassionate Access Program

Germany has become the first country in the European Union to allow legal access to a psychedelic, under certain conditions, prior to regulatory approval.

Through a newly established compassionate use program—which has received the blessing of the country’s drug regulator, the Federal Institute for Drugs and Medical Devices (BfArM)—two facilities are now able to offer psilocybin to adults with treatment-resistant depression (TRD).

Those two clinics, the Central Institute of Mental Health (CIMH, also known as ZI Mannheim) and the OVID Clinic Berlin, expect demand will far outpace capacity. There, psychiatrists will admit qualified patients to receive Filament Health’s botanical psilocybin candidate, PEX010, in the context of a broader psychiatric care protocol.

Psychedelic Alpha spoke with Gerhard Gründer, who submitted the successful application and will lead the roll-out of the compassionate use program, to learn more about this development.

Keep reading

Psychedelic Drug May Slow Aging

Could magic mushrooms hold the key to slowing down aging? New research from Georgia’s Emory University suggests they just might.

A new study has found that psilocin—a compound produced in the body after consuming psilocybin, the active ingredient in psychedelic mushrooms—extended the lifespan of human skin and lung cells in the lab by more than 50 percent.

The researchers also found that mice treated with psilocybin lived 30 percent longer—not to mention more healthily—than their peers.

“This study provides strong preclinical evidence that psilocybin may contribute to healthier aging—not just a longer lifespan, but a better quality of life in later years,” Dr. Ali John Zarrabi, Director of Psychedelic Research at Emory University’s Department of Psychiatry said in a statement.

“As a palliative care physician-scientist, one of my biggest concerns is prolonging life at the cost of dignity and function. But these mice weren’t just surviving longer—they experienced better aging,” added Zarrabi, who co-led the study.

As part of their study, the researchers ran the first long-term assessment of psilocybin’s systemic effects in living animals.

They treated aged, 19-month-old mice—which is something like 60–65 in human years—with an initially low psilocybin dose of 5 mg, followed by a high dose of 15 mg every month for 10 months.

The team found that psilocybin-treated mice survived around 30 percent longer than their untreated peers. Moreover, the treated mice also looked healthier for it, with better fur quality, fewer white hairs and even hair regrowth.

While psilocybin is usually studied for its mental health benefits, the findings suggest that the compound may also tackle key drivers of aging.

According to the team, the psilocybin treatments reduced oxidative stress, improved the cells’ ability to repair DNA and helped preserve the length of telomeres—the protective caps on chromosomes that guard against damage leading to diseases like cancer, neurodegeneration and heart disease.

“Most cells in the body express serotonin receptors, and this study opens a new frontier for how psilocybin could influence systemic aging processes, particularly when administered later in life,” said senior author and former Emory professor Louise Hecker in a statement.

Though psilocybin may be best known for its hallucinogenic effects on the brain, most cells in the body have serotonin receptors, suggesting it could have much wider impacts.

Keep reading

Psilocybin treatment extends cellular lifespan and improves survival of aged mice

Psilocybin, the naturally occurring psychedelic compound produced by hallucinogenic mushrooms, has received attention due to considerable clinical evidence for its therapeutic potential to treat various psychiatric and neurodegenerative indications. However, the underlying molecular mechanisms remain enigmatic, and few studies have explored its systemic impacts. We provide the first experimental evidence that psilocin (the active metabolite of psilocybin) treatment extends cellular lifespan and psilocybin treatment promotes increased longevity in aged mice, suggesting that psilocybin may be a potent geroprotective agent.

Introduction
To date, >150 clinical studies with psilocybin have been completed or are ongoing for various clinical indications, including psychiatric (anxiety, depression, addiction), neurodegenerative (Alzheimer’s), pain, and more1,2,3. Human studies have demonstrated that a single-dose of psilocybin can improve debilitating physical and psychological symptoms—with durable effects (up to ~5 years)4,5. Despite considerable clinical evidence supporting the therapeutic benefits of psilocybin, the molecular mechanisms responsible for these impacts remain enigmatic. Studies with psilocybin have predominantly focused on neurological impacts and/or behavioral outcomes; few studies have evaluated alternative or systemic mechanisms which may also contribute to its beneficial effects. The “psilocybin-telomere hypothesis”6 postulates that psilocybin interventions may quantifiably impact telomere length, which offers a potential explanation for its efficacy across a wide range of clinical indications. This hypothesis is based on a large corpus of studies linking mental health biological aging markers6. Accumulating evidence indicate that clinical depression accelerates aging and telomere shortening7,8,9. Positive mental psychological states are associated with longer telomeres, whereas negative psychological conditions (e.g. chronic stress, anxiety, and depression) are associated with telomere attrition7,10,11,12,13. Given the clinical evidence supporting the efficacy of psilocybin for these conditions, it is plausible that psilocybin may impact telomere length. However, no prior studies have experimentally investigated the direct impact of psilocybin on biological aging.

Keep reading

Czech Republic Bill To Legalize Marijuana Home Cultivation And Allow Psilocybin For Medical Use Heads To President’s Desk

Lawmakers in the Czech Republic have passed a bill to reform the nation’s drug laws by legalizing simple possession and home cultivation of marijuana and allowing the use of psilocybin for medical purposes.

One month after the Chamber of Deputies approved the legislation, the Senate gave it final approval on Thursday. It now heads to the desk of President Petr Pavel to be signed into law.

The drug policy reforms are part of a package of amendments to the Czechia’s criminal code that supporters say will reduce spending on low-priority offenses, lower the number of people behind bars and reduce recidivism.

“The amendment will help criminal law better distinguish between truly socially harmful behavior and cases that do not belong in criminal proceedings at all,” outgoing Justice Minister Pavel Blažek said last month, according to a translated report from broadcaster Česká Televize (CT).

With respect to cannabis, the proposal would legalize possession of up to 100 grams of marijuana at home or 25 grams in public. Cultivation of up to three plants would also be allowed, though four or five plants would be a misdemeanor and more than that would be a felony. Possession of more than 200 grams would also carry criminal penalties.

Keep reading

Iowa Lawmaker Supporting Medical Psilocybin Bashes Bill That Would’ve Legalized Only A Synthetic Version Of The Psychedelic

An Iowa lawmaker who pushed for the passage of a bill to create a state program allowing the medicinal use of psilocybin said Gov. Kim Reynolds’s (R) decision to veto a bill pertaining to the psychoactive compound in magic mushrooms was a “great decision.”

Rep. Jeff Shipley (R-Fairfield) said rather than focus on rescheduling a synthetic version of the drug, the state should instead prioritize creating a state program legalizing the psychiatric use of naturally occurring psilocybin.

House File 383 would have allowed for the prescription and distribution of synthetic psilocybin immediately following federal approval of the drug, and mirrored a similar bill, which was signed into law, in Colorado.

The bill dealt with crystalline polymorph psilocybin, a compound commonly known as COMP360, which is a treatment developed by the biotechnology company Compass Pathways to help patients with treatment of resistant depression, post traumatic stress disorder and anorexia nervosa.

Shipley said he “condemns Compass Pathways” for its approach at creating, and patenting, a synthetic version of the “natural psilocybin that God has given us that everyone knows and loves.”

Compass Pathways declined to comment on the veto of the bill, which it lobbied in support of, and on Shipley’s comment.

Shipley’s emailed statement also apologized for his vote in favor of the bill, which passed unanimously in both the House and Senate.

“The proper legal framework is to reschedule psilocybin to schedule IV or III, and allow the relevant state regulatory boards to make it available as medicine,” Shipley said.

Reynolds, in her explanation of the veto, similarly said the state should have time to review any federal action on the synthetic version of the drug before it legalizes it at the state level.

Shipley was a vocal supporter of House File 978, which would have legalized the use of psilocybin for psychiatric treatment through a state program. The proposed program would have operated similarly to the state’s medical cannabis program.

The bill passed the House with an overwhelming majority in late April, but was not taken up by the Senate.

Keep reading

Just one single dose of ‘magic mushrooms’ could relieve depression for 5 years, researchers find

Psilocybin, the main psychoactive ingredient in magic mushrooms, could alleviate depression for at least five years after just one dose, according to a new study.

The research, presented June 18 at the Psychedelic Science 2025 conference in Denver, followed up with patients who had been diagnosed with clinical depression — also known as major depressive disorder (MDD) — and had participated in a previous psilocybin treatment study in 2020.

“Most people who participated in our trial reported improvements in depression symptom intensity or in the ways in which they experienced depression in their life, lasting up to five years after the trial,” study co-author Alan Davis, director of the Center for Psychedelic Drug Research and Education at The Ohio State University, told Fox News Digital.

Doug Drysdale, CEO of the Canadian pharmaceutical company Cybin in Toronto, Ontario, told Fox News Digital that the outcome speaks to the “exciting” potential of psilocybin and other psychedelic-based treatments in treating MDD and other mental health conditions.

“The results of the study are certainly very encouraging,” said Drysdale, who was not involved in the study.

Earlier studies pointed toward the possibility of psilocybin as a potential antidepressant, prompting researchers to conduct the first-ever randomized clinical trial.

Keep reading

Utah Passed a Religious Freedom Law. Then Cops Went After This Psychedelic Church.

When Bridger Lee Jensen opened a spiritual center in Provo, Utah, he contacted city officials to let them know the religious group he had founded, Singularism, would be conducting ceremonies involving a tea made from psilocybin mushrooms. “Singularism is optimistic that through partnership and dialogue, it can foster an environment that respects diversity and upholds individual rights,” Jensen wrote in a September 2023 letter to the Provo City Council and Mayor Michelle Kaufusi. Seeking to “establish an open line of communication” with local officials, Jensen invited them to ask questions and visit the center.

Jensen’s optimism proved to be unfounded. The city did not respond to his overture until more than a year later, when Provo police searched the Singularism center and seized the group’s sacrament: about 450 grams of psilocybin mushrooms from Oregon. The seizure resulted from an investigation in which an undercover officer posed as a would-be Singularism facilitator.

That raid happened in November 2024, less than eight months after Utah Gov. Spencer Cox, a Republican, had signed the state’s version of the federal Religious Freedom Restoration Act (RFRA). The state law likely protects Singularism’s psychedelic rituals, a federal judge ruled in February. U.S. District Judge Jill Parrish granted Jensen’s request for a preliminary injunction against city and county officials, ordering them to return the mushrooms and refrain from further interference with the group’s “sincere religious use of psilocybin” while the case is pending.

“In this litigation, the religious-exercise claims of a minority entheogenic religion put the State of Utah’s commitment to religious freedom to the test,” Parrish wrote in Jensen v. Utah County. If such a commitment “is to mean anything,” she said, it must protect “unpopular or unfamiliar religious groups” as well as “popular or familiar ones.”

Parrish noted that “the very founding of the State of Utah reflects the lived experience of that truth by members of the Church of Jesus Christ of Latter-day Saints.” In light of that history, she suggested, “it is ironic” that “not long after enacting its RFRA to provide special protections for religious exercise, the State of Utah should so vigorously deploy its resources, particularly the coercive power of its criminal-justice system, to harass and shut down a new religion it finds offensive practically without any evidence that [the] religion’s practices have imposed any harms on its own practitioners or anyone else.”

Under the federal RFRA, which Congress enacted in 1993, the government may not “substantially burden a person’s exercise of religion” unless it shows that the burden is “the least restrictive means” of furthering a “compelling governmental interest.” In 2006, the Supreme Court unanimously ruled that RFRA protected the American branch of a syncretic Brazil-based church from federal interference with its rituals, even though the group’s sacramental tea, ayahuasca, contained the otherwise illegal psychedelic drug dimethyltryptamine.

The Supreme Court has said RFRA cannot be applied to state and local governments. Laws like Utah’s, which 29 states have enacted, aim to fill that gap.

The defendants in Jensen’s case—Utah County Attorney Jeffrey Gray, the county, and the city of Provo—argued that Utah’s RFRA did not apply to Singularism, which they portrayed as a drug trafficking operation disguised as a religion. Parrish rejected that characterization. “Based on all the evidence in the record,” she wrote, “the court has no difficulty concluding that Plaintiffs are sincere in their beliefs and that those beliefs are religious in nature.”

Parrish also concluded that “preventing Singularism’s adherents from pursuing their spiritual voyages” imposed a substantial burden on their religious freedom that was not “the least restrictive means” of addressing the government’s public safety concerns. She noted that Utah allows religious use of peyote and has authorized “behavioral health treatment programs” in which patients can receive psilocybin.

Keep reading